<DOC>
	<DOC>NCT01646671</DOC>
	<brief_summary>This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients</brief_summary>
	<brief_title>Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients</brief_title>
	<detailed_description>Summaries for treatment-emergent adverse events, serious adverse events and death were provided by the following actual treatment regimen (actual treatment patients received) in addition to all patients: LCZ696 200mg, 400mg, 400mg+other hypertensive medications. Summaries for others than above were provided by the following treatment regimen (determined by the maximal treatment patients received) in addition to all patients: LCZ696 200mg, 400mg, 400mg+other hypertensive medications.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Satisfy office msSBP ≥180 mmHg or office msDBP ≥110 mmHg at baseline Patients show msSBP ≥220 mmHg and/or msDBP ≥120 mmHg History of angioedema, drugrelated or otherwise, as reported by the patient Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol. Patients have significant cardiovascular comorbidities Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch. Other protocol defined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hypertension, Severe, LCZ696</keyword>
</DOC>